Key result
Intravenous zatebradine significantly prolonged sinus cycle length by 16 and 17% (p<0.001) and altered atrioventricular node conduction compared to placebo.
Why the study?
Does intravenous zatebradine alter electrophysiologic properties in patients without structural heart disease?
Population
35 patients without structural heart disease
Comparison
Intravenous zatebradine vs Placebo
Design
RCT, randomized, Double-Blind Placebo-Controlled
Follow-up
70 minutes
Authors
Loading...
Informs rate-control drug selection in patients without heart disease; extends animal sinus node data to human electrophysiology.
RCT (n=35)
Double-blind
randomized
Does intravenous zatebradine alter electrophysiologic properties in patients without structural heart disease?
Effect estimate: 16 and 17% prolongation
p-value: p=<0.001
Zatebradine, a sinus node inhibitor, significantly alters both sinus node and atrioventricular node conduction and refractory properties in humans.
Chiamvimonvat et al. (1998) conducted an RCT in Without structural heart disease (n=35). Zatebradine vs. Placebo was evaluated on Sinus cycle length (16 and 17% prolongation, p=<0.001). Intravenous zatebradine significantly prolonged sinus cycle length by 16 and 17% (p<0.001) and altered atrioventricular node conduction compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: